title: Effect of Lactobacillus sakei supplementation in children with atopic eczema-dermatitis syndrome.
abstract: BACKGROUND
  Probiotics have been suggested to be useful in children with atopic eczema-dermatitis syndrome (AEDS).
  
  
  OBJECTIVE
  To assess the clinical effect of Lactobacillus sakei supplementation in children with AEDS.
  
  
  METHODS
  In a double-blind, placebo-controlled trial, children aged 2 to 10 years with AEDS with a minimum SCORing of Atopic Dermatitis (SCORAD) score of 25 were randomized to receive either daily L sakei KCTC 10755BP or daily placebo supplementation for 12 weeks. Changes in SCORAD scores and serum chemokine levels from baseline were evaluated.
  
  
  RESULTS
  Eighty-eight children were enrolled, and 45 were allocated to probiotic treatment. Seventy-five children completed the study, with 4 dropouts in the probiotic group and 9 in the placebo group. At week 12, SCORAD total scores adjusted by pretreatment values were lower after probiotic treatment than after placebo treatment (P = .01). There was a 31% (13.1-point) improvement in mean disease activity with probiotic use compared with a 13% (5.2-point) improvement with placebo use (P = .008). Significant differences in favor of probiotic treatment were also observed in proportions of patients achieving improvement of at least 30% and 50%. Compared with placebo, probiotic administration was associated with lower pretreatment-adjusted serum levels of CCL17 and CCL27 (P =.03 for both), which were significantly correlated with SCORAD total score (r = 0.59 and 0.63, respectively; P < .001).
  
  
  CONCLUSIONS
  Supplementation of L sakei in children with AEDS was associated with a substantial clinical improvement and a significant decrease in chemokine levels, reflecting the severity of AEDS.
authors.affiliation: Department of Pediatrics, College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Korea.
authors.forename: Sung-Il
authors.initials: SI
authors.lastname: Woo
authors.forename: Ji-Yoon
authors.initials: JY
authors.lastname: Kim
authors.forename: Yong-Ju
authors.initials: YJ
authors.lastname: Lee
authors.forename: Nam-Shik
authors.initials: NS
authors.lastname: Kim
authors.forename: Youn-Soo
authors.initials: YS
authors.lastname: Hahn
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D054414:Chemokine CCL17 / Q000097:blood; D054425:Chemokine CCL27 / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000097:blood / Q000175:diagnosis / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007778:Lactobacillus; D008297:Male; D019936:Probiotics / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; C106230:CCL17 protein, human; C492276:CCL27 protein, human; D054414:Chemokine CCL17; D054425:Chemokine CCL27